文献速递骨软组织肉瘤与黑色素瘤

新辅助BO-112联合大分割放疗±纳武利尤单抗治疗软组织肉瘤的临床前与I期结果

Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results.
PubMed 文献 · Cancer Discov · 2026-01-01

该I期新辅助试验在14例高危软组织肉瘤患者中评估肿瘤内BO-112联合大分割放疗±纳武利尤单抗。三联方案诱导了罕见的免疫相关不良事件(肌炎-心肌炎-重症肌无力谱系),可通过调整BO-112和纳武利尤单抗剂量缓解。BO-112和放疗使肿瘤相关髓系细胞向抗原呈递状态重编程,促进克隆替换为耗竭更少的T细胞,并增强恶性细胞清除,在小样本高危队列中伴随疾病控制的鼓舞性结果。

要点

  • 肿瘤内BO-112联合大分割放疗在临床前模型中激活全身T细胞免疫。
  • I期试验纳入14例高危可切除软组织肉瘤患者评估三联方案。
  • 三联方案诱导罕见免疫相关不良事件,剂量调整可缓解。

核心结论

  • 肿瘤内BO-112联合大分割放疗±纳武利尤单抗在临床前模型和I期新辅助研究中激活全身T细胞免疫。
  • BO-112通过调动髓系细胞,与放疗联合是补充T细胞缺陷肿瘤并扩展新辅助ICB获益的强效策略。

研究设计与样本

  • 临床前模型研究联合I期新辅助试验,纳入14例高危软组织肉瘤患者。
  • 患者接受肿瘤内BO-112联合大分割放疗,联合或不联合纳武利尤单抗。

主要发现

  • 三联组合诱导罕见的免疫相关不良事件(肌炎-心肌炎-重症肌无力谱系),通过调整BO-112和纳武利尤单抗剂量缓解。
  • BO-112和放疗使肿瘤相关髓系细胞向抗原呈递状态重编程。
  • BO-112和放疗促进克隆替换为耗竭更少的T细胞,并较标准放疗增强恶性细胞清除。
  • 免疫学变化在小样本高危队列中伴随鼓舞性的疾病控制。

临床怎么用

  • BO-112联合大分割放疗±纳武利尤单抗方案需关注罕见免疫相关不良事件(肌炎-心肌炎-重症肌无力谱系)。
  • 通过调整BO-112和纳武利尤单抗剂量可缓解上述免疫相关不良事件。
  • 该策略支持进一步临床开发。

局限性

  • I期试验样本量小(14例),结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Neoadjuvant immune checkpoint blockade (ICB) and radiotherapy (RT) improve disease-free survival in select patients with soft-tissue sarcoma (STS). However, most STS are myeloid-rich and lack preexisting T cells associated with ICB response. In preclinical models, we observed that intratumoral BO-112 [nanoplexed polyinosinic: polycytidylic acid (poly I:C)] engages myeloid cells that persist after RT, ultimately enhancing T cell-dependent tumor control. We evaluated BO-112 and hypofractionated RT, with or without nivolumab, in 14 patients with high-risk STS in a phase I neoadjuvant trial. Consistent with its immunologic potency, the triple combination induced rare immune-related adverse events (myositis-myocarditis-myasthenia gravis spectrum), mitigated by BO-112 and nivolumab dose adjustment. BO-112 and RT reprogrammed tumor-associated myeloid cells toward antigen-presenting states, promoted clonal replacement by less exhausted T cells, and enhanced malignant cell depletion compared with standard RT. These immunologic changes coincided with encouraging disease control in a small, high-risk cohort, supporting further clinical development. SIGNIFICANCE: Intratumoral BO-112 and hypofractionated RT activate systemic T-cell immunity in mouse models and in a phase I neoadjuvant study of high-risk, resectable sarcoma. Engaging myeloid cells with BO-112 represents a potent strategy with RT to replete T cell-deficient tumors and expand the benefits of neoadjuvant ICB.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Deng J, Pal A, Testa S, et al. Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results. Cancer Discov. 2026. PMID: 41784328. doi:10.1158/2159-8290.CD-25-1132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。